Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gene polymorphism effects on dabigatran and rivaroxaban efficacy in venous thromboembolism
ChiCTR1800019890Phase 4Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dabigatran and rivaroxaban in venous thromboembolism (VTE) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Gene polymorphism. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
dabigatranrivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on ChiCTR1800019890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019890.